<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Dec. 11, 2019 (HealthDay News) — Low-dose aspirin is used less consistently by blacks than whites for the primary prevention of cardiovascular disease (CVD), and its impact on ischemic cardiac disease varies by race, according to a study published online Dec. 11 in the Journal of the American Heart Association<\/i>.<\/p>\n
Rodrigo Fern\u00e1ndez-Jim\u00e9nez, M.D., Ph.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined patterns of low-dose aspirin use and its role in the prevention of CVD among 65,231 non-Hispanic black and white adults aged 40 to 79 years with no history of CVD.<\/p>\n
The researchers found that regardless of CVD risk and significant covariates, blacks were less likely to take low-dose aspirin than whites (adjusted odds ratio, 0.79; 95 percent confidence interval [CI], 0.75 to 0.82). Low-dose aspirin was associated with a trend toward a reduced risk for ischemic cardiac deaths in whites during a median follow-up of 11.3 years (adjusted hazard ratio [aHR], 0.86; 95 percent CI, 0.68 to 1.10), especially in women (aHR, 0.72; 95 percent CI, 0.51 to 1.02); this trend was not seen in blacks (aHR, 1.18; 95 percent CI, 0.98 to 1.40). When the analysis was restricted to high-risk individuals aged 50 to 69 years or 50 to 59 years, the results were similar.<\/p>\n
“Although additional studies are required, these findings provide no evidence of a beneficial effect of aspirin use among blacks for CVD primary prevention,” the authors write.<\/p>\n